US EditionBreakthrough: New Multiple Myeloma Drug Achieves 95% Survival Rate in 4-Year Clinical Trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma
Scientists determined the myeloablative efficacy of C-X-C motif chemokine receptor 4 (CXCR4) radioligand therapy in multiple myeloma patients and assessed the safety profile of this treatment. [Clinical Nuclear Medicine] Full Article
EU committee recommends Blenrep combos for approval in RRMM
A committee of the European Medicines Agency has recommended approving GSK’s Blenrep (belantamab mafodotin) in combination with other therapeutic agents to treat relapsed or refractory multiple myeloma (RRMM). The recommendation from the Committee for Medicinal Products for Human Use (CHMP) covers Blenrep in combination with Velcade (bortezomib) plus dexamethasone (BorDex), or Pomalyst (pomalidomide) plus dexamethasone (PomDex) in patients who’v…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
